Block Listing Six Monthly Return

RNS Number : 9320T

Futura Medical PLC

30 November 2021

 

Block Listing Six Monthly Return

30 November 2021

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Date: 1 June 2021

Name of applicant:		Futura Medical Plc
Name of scheme:		Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme
Period of return:	From:	1 June 2021	To:	30 November 2021
Balance of unallotted securities under scheme(s) from previous return:		7,811,779
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		n/a
Less:   Number of securities issued/allotted under scheme(s) during period:		(80,000)
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		7,731,779
Number and class of securities originally admitted and the date of admission		USOS Total: 3,882,912 814,424                25 May 2011 1,202,280  8 October 2013 1,466,208  25 May 2017 400,000                30 May 2018 USIS Total: 425,000 425,000                30 November 2018 EMI Total: 7,012,088 1,520,576  25 May 2011 1,467,720  8 October 2013 1,893,792  25 May 2017 790,000                30 May 2018 1,340,000             30 November 2018

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]
 

Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Kane Collings

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel [phone]

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys^® technology. Each DermaSys^® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.  www.futuramedical.com

 

END

 

 

BLRUKRNRAWUAUAA